000			03095nam a2200361| 4500
001			85969
005			20220308123207.0
010			_a978-4-431-55573-5 _dcompra
090			_a85969
100			_a20190128d2018 k||y0pory50 ba
101	0		_aeng
102			_aUS
200	1		_aModern dose-finding designs for cancer phase I trials _bDocumento electrn̤ico _edrug combinations and molecularly targeted agents _fAkihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui
210			_aTokyo _cSpringer Japan _cSpringer _d2018
215			_aXIII, 89 p. _cil.
225	2		_aJSS Research Series in Statistics
300			_aColocaȯ̂: Online
303			_aThis book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considerations in applying these complex methods to real cancer clinical trials. Thus, the book aims to furnish researchers in biostatistics and statistical science with a good summary of recent developments of adaptive dose-finding methods as well as providing practitioners in biostatistics and clinical investigators with advanced materials for designing, conducting, monitoring, and analyzing adaptive dose-finding trials. The topics in the book are mainly related to cancer clinical trials, but many of those topics are potentially applicable or can be extended to trials for other diseases. The focus is mainly on model-based dose-finding methods for two kinds of phase I trials. One is clinical trials with combinations of two agents. Development of dose-finding methods for two-agent combination trials requires reasonable models that can adequately capture joint toxicity probabilities for two agents, taking into consideration possible interactions of the two agents on toxicity probability such as synergistic or antagonistic effects. Another is clinical trials for evaluating both efficacy and toxicity outcomes in single- and two-agent combination trials. These methods are often applied to the phase I trials including MTAs because the toxicity and efficacy for a MTA does not monotonically increase with dose, but the efficacy often increases initially with the dose and then plateaus. Successful software implementations for several dose-finding methods are introduced in the book, and their operating characteristics in practice are discussed. Recent advance of the adaptive dose-finding methods in drug developments are also provided.
410	1		_x2364-0057
606			_93627 _aEstats̕tica
606			_91379 _aEstats̕tica matemt̀ica
606			_911537 _aMťodos estats̕ticos
680			_aQA276
700			_965670 _aHirakawa _bAkihiro
702			_965671 _aAkihiro _bHiroyuki
702			_965672 _aDaimon _bTakashi
702			_964699 _aMatsui _bShigeyuki
801		0	_gRPC _aPT
856			_uhttps://doi.org/10.1007/978-4-431-55573-5
942			_2lcc _cF _n0